(1-叔-丁氧羰基吡咯-3-基)硼酸 | 832697-40-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: (1-叔-丁氧羰基吡咯-3-基)硼酸
• 中文别名: 1-N-BOC-吡咯-3-硼酸
• 英文名称: (1-(tert-butoxycarbonyl)-1H-pyrrol-3-yl)boronic acid
• 英文别名: 1-(tert-Butoxycarbonyl)pyrrole-3-boronic acid；[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrol-3-yl]boronic acid
• CAS: 832697-40-2
• 化学式: C₉H₁₄BNO₄
• 分子量: 211.025
• InChiKey: JTFQDOHHXGSMFC-UHFFFAOYSA-N

物化性质

• 沸点：
  361.4±52.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.05
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  71.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (1-叔-丁氧羰基吡咯-3-基)硼酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives

  摘要：

  HTS screening identified compound 2a (piper-azinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p-fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and la potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.

  DOI：

  10.1021/jm4012643
• 作为产物：
  描述：

  硼酸三甲酯 、 3-bromo-1-(tert-butoxycarbonyl)pyrrole 在 正丁基锂 、 甲醇 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.41h， 以47%的产率得到(1-叔-丁氧羰基吡咯-3-基)硼酸
  参考文献：
  名称：

  Development of a Brønsted Acid-Promoted Arene–Ynamide Cyclization toward the Total Syntheses of Marinoquinolines A and C and Aplidiopsamine A

  摘要：

  A Bronsted acid-promoted arene-ynamide cyclization has been developed to construct the 3H-pyrrolo[2,3-c]quinolines. This reaction consists of the generation of a highly reactive keteniminium intermediate from arene-ynamide activated by a Bronsted acid and electrophilic aromatic substitution reaction to give arene-fused quinolines in high yields. This methodology enabled facile access to marinoquinolines A and C and aplidiopsamine A.

  DOI：

  10.1021/jo502467m

文献信息

• [EN] SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR<br/>[FR] LIGANDS SÉLECTIFS DU RÉCEPTEUR D'ANDROSTANE CONSTITUTIF HUMAIN
  申请人：USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I

  公开号：WO2020221380A1

  公开（公告）日：2020-11-05

  The present invention provides a structurally novel class of heterocyclic compounds of general formula I wherein L1 is heteroaryl and L2 is heteroaryl or aryl. The novel compounds are useful in a method of prevention or treatment of a condition which is mediated by the action, or by loss of action, of Constitutive androstane receptor (CAR) receptor or its endogenous ligands. The present invention thus provides the novel compounds for medicinal use, as well as pharmaceutical composition containing said compounds. (I)

  本发明提供了一类结构新颖的杂环化合物，其通用公式为I，其中L1是杂芳基，L2是杂芳基或芳基。这些新颖化合物在预防或治疗由构成雄烷受体（CAR）受体或其内源性配体的作用或作用丧失介导的疾病的方法中是有用的。因此，本发明提供了用于药用的新颖化合物，以及含有所述化合物的药物组合物。(I)
• Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives
  作者：Ramesh Kakarla、Jian Liu、Devan Naduthambi、Wonsuk Chang、Ralph T. Mosley、Donghui Bao、Holly M. Micolochick Steuer、Meg Keilman、Shalini Bansal、Angela M. Lam、William Seibel、Sandra Neilson、Phillip A. Furman、Michael J. Sofia

  DOI：10.1021/jm4012643

  日期：2014.3.13

  HTS screening identified compound 2a (piper-azinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p-fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and la potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.
• Development of a Brønsted Acid-Promoted Arene–Ynamide Cyclization toward the Total Syntheses of Marinoquinolines A and C and Aplidiopsamine A
  作者：Yousuke Yamaoka、Takahiro Yoshida、Makiko Shinozaki、Ken-ichi Yamada、Kiyosei Takasu

  DOI：10.1021/jo502467m

  日期：2015.1.16

  A Bronsted acid-promoted arene-ynamide cyclization has been developed to construct the 3H-pyrrolo[2,3-c]quinolines. This reaction consists of the generation of a highly reactive keteniminium intermediate from arene-ynamide activated by a Bronsted acid and electrophilic aromatic substitution reaction to give arene-fused quinolines in high yields. This methodology enabled facile access to marinoquinolines A and C and aplidiopsamine A.